269 related articles for article (PubMed ID: 16168711)
1. Scleroderma: from cell and molecular mechanisms to disease models.
Abraham DJ; Varga J
Trends Immunol; 2005 Nov; 26(11):587-95. PubMed ID: 16168711
[TBL] [Abstract][Full Text] [Related]
2. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
Shiwen X; Leask A; Abraham DJ; Fonseca C
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
[TBL] [Abstract][Full Text] [Related]
3. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.
Cipriani P; Guiducci S; Miniati I; Cinelli M; Urbani S; Marrelli A; Dolo V; Pavan A; Saccardi R; Tyndall A; Giacomelli R; Cerinic MM
Arthritis Rheum; 2007 Jun; 56(6):1994-2004. PubMed ID: 17530639
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of adhesion molecules and chemokines in scleroderma.
Sato S
Curr Opin Rheumatol; 1999 Nov; 11(6):503-7. PubMed ID: 10551675
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic autoantibodies in systemic sclerosis.
Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
[TBL] [Abstract][Full Text] [Related]
6. Vascular and epithelial junctions: a barrier for leucocyte migration.
Garrido-Urbani S; Bradfield PF; Lee BP; Imhof BA
Biochem Soc Trans; 2008 Apr; 36(Pt 2):203-11. PubMed ID: 18363562
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of scleroderma: an update.
Haustein UF; Anderegg U
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):1-8. PubMed ID: 9731958
[TBL] [Abstract][Full Text] [Related]
8. Induction of endothelial cell damage by hCMV molecular mimicry.
Lunardi C; Bason C; Corrocher R; Puccetti A
Trends Immunol; 2005 Jan; 26(1):19-24. PubMed ID: 15629405
[TBL] [Abstract][Full Text] [Related]
9. Scleroderma--pathophysiology.
Yamamoto T
Eur J Dermatol; 2009; 19(1):14-24. PubMed ID: 19059831
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
Guiducci S; Distler O; Distler JH; Matucci-Cerinic M
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v18-20. PubMed ID: 18784130
[TBL] [Abstract][Full Text] [Related]
11. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis.
Chizzolini C
Curr Opin Rheumatol; 2008 Nov; 20(6):707-12. PubMed ID: 18946333
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M; Varga J
Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
[TBL] [Abstract][Full Text] [Related]
13. The immunobiology of systemic sclerosis.
Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
[TBL] [Abstract][Full Text] [Related]
14. Immunological basis of systemic sclerosis.
Zuber JP; Spertini F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii23-5. PubMed ID: 16987826
[TBL] [Abstract][Full Text] [Related]
15. [Pathophysiology of systemic sclerosis].
Allanore Y
Med Sci (Paris); 2016 Feb; 32(2):183-91. PubMed ID: 26936176
[TBL] [Abstract][Full Text] [Related]
16. Role of IL-13 in systemic sclerosis.
Fuschiotti P
Cytokine; 2011 Dec; 56(3):544-9. PubMed ID: 21920770
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy comes of age in scleroderma.
Denton CP; Black CM
Trends Immunol; 2005 Nov; 26(11):596-602. PubMed ID: 16168710
[TBL] [Abstract][Full Text] [Related]
19. Disease models of autoimmunity.
Ferguson CA
Trends Immunol; 2005 Nov; 26(11):557-8. PubMed ID: 16182605
[No Abstract] [Full Text] [Related]
20. Animal models of fibrosis.
Bocchieri MH; Jimenez SA
Rheum Dis Clin North Am; 1990 Feb; 16(1):153-67. PubMed ID: 2406805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
